Rybrevant package insert

Any changes in the manufacturing, testing, packaging, or labeling of RYBREVANT, or in Prescribing Information and Patient Package Insert.

The official patient website for RYBREVANT (amivantamab-vmjw), a treatment for common EGFR NSCLC and EGFR NSCLC with exon 20 insertion mutations.

Absence of unacceptable toxicity from the drug. Examples of Rybrevant [package insert]. Horsham, PA; Janssen Biotech, Inc

Rybrevant 350 mg/7 mL (50 mg/mL) solution as a single-dose vial: xx VII. References 1. Rybrevant [package insert]. Horsham, PA; Janssen Biotech, Inc.; December 2024. Accessed March 2024. 2. Referenced with permission from the NCCN Drugs Biologics Compendium (NCCN Compendium ) for amivantamab.

1Eliquis package insert 2 Pradaxa package insert 3Savaysa package insert 4 Xarelto package insert. CrCl should be based on the Cockcroft-Gault formula

Rybrevant (amivantamab-vmjw) [package insert] . Raritan, NJ. : Janssen Biotech, Inc. ;. 2024 . 16. U.S. Food and Drug Administration . Drug

For adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. FIRST-LINE TREATMENT WITH RYBREVANT :

Amivantamab. Rybrevant. Extended indication, Amivantamab in combination with insertion mutations. Therapeutic value, No estimate possible yet.

by V Shah 2024 Cited by 4Horsham P.A. Amivantamab-Vmjw (Rybrevant) [Package Insert] Janssen Biotech; Horsham Township, PA, USA: 2024. [Google Scholar]. 16. Zhang Z